GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Net Income

KYMR (Kymera Therapeutics) Net Income : $-223.86 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Kymera Therapeutics's Net Income for the three months ended in Dec. 2024 was $-70.75 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-223.86 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Kymera Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.88.


Kymera Therapeutics Net Income Historical Data

The historical data trend for Kymera Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Net Income Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial -45.59 -100.22 -154.81 -146.96 -223.86

Kymera Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.37 -48.56 -42.06 -62.49 -70.75

Kymera Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Kymera Therapeutics's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-223.858+0+0+0
=-223.86

Kymera Therapeutics's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-70.752+0+0+0
=-70.75

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-223.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kymera Therapeutics  (NAS:KYMR) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Kymera Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Kymera Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Kymera Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Executives
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Pamela Esposito director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472